NR1H4 and Hepatic fibrosis: In addition, the FXR ligands treatment increased the peroxisome proliferator-activated receptor (PPAR)-γ mRNA levels in the HSCs and in the rodent models of liver fibrosis, leading to the inhibition of the HSCs activation [47].